View More Recent Stories

Dec 10, 2021 07:00AM Clene Nanomedicine to Present RESCUE-ALS Phase 2 Data in Late-Breaking Session at 32nd International Symposium on ALS/MND
Dec 7, 2021 07:00AM Clene Nanomedicine’s RESCUE-ALS Phase 2 Results Selected for Late-Breaking Presentation at 32nd International Symposium on ALS/MND
Dec 7, 2021 07:00AM Clene Nanomedicine’s RESCUE-ALS Phase 2 Results Selected for Late-Breaking Presentation at 32nd International Symposium on ALS/MND
Dec 1, 2021 07:02AM Clene (CLNN) Reports Updated Data from RESCUE-ALS Phase 2 Study
Dec 1, 2021 07:00AM Clene Nanomedicine Presents Updated Data from RESCUE-ALS Phase 2 Study at 4th Annual ALS ONE Research Symposium
Dec 1, 2021 07:00AM Clene Nanomedicine Presents Updated Data from RESCUE-ALS Phase 2 Study at 4th Annual ALS ONE Research Symposium
Nov 15, 2021 08:48AM Clene Announces Completion of Patient Enrollment in the HEALEY ALS Platform Trial
Nov 15, 2021 08:48AM Clene Announces Completion of Patient Enrollment in the HEALEY ALS Platform Trial
Nov 9, 2021 07:00AM Clene Reports Third Quarter 2021 Operating and Financial Highlights
Nov 9, 2021 07:00AM Clene Reports Third Quarter 2021 Operating and Financial Highlights
Nov 2, 2021 07:03AM Clene (CLNN) Phase 2 RESCUE-ALS Clinical Trial Did Not Meet Primary or Secondary Endpoints
Nov 2, 2021 07:02AM Clene (CLNN) Reports Phase 2 RESCUE-ALS Trial Did Not Meet Endpoints
Nov 2, 2021 07:00AM Clene Nanomedicine Announces Top-Line Results from Phase 2 RESCUE-ALS Clinical Trial
Nov 2, 2021 07:00AM Clene Nanomedicine Announces Top-Line Results from Phase 2 RESCUE-ALS Clinical Trial
Sep 23, 2021 07:00AM Clene Announces Initiation of a Second FDA Expanded Access Program with CNM-Au8 for People Living with Amyotrophic Lateral Sclerosis
Sep 17, 2021 07:00AM Clene Presents Phase 2 CNM-Au8 CNS Target Engagement Data at the International Parkinson and Movement Disorder Society Virtual Congress 2021
Sep 9, 2021 07:00AM Clene Completes Final Patient Visit in Phase 2 RESCUE-ALS Study: Topline Data Readout Expected Q4 2021
Aug 31, 2021 07:00AM Clene Nanomedicine to Present at Upcoming Virtual Investor Conferences
Aug 11, 2021 07:00AM Clene Enters into Two Leases to Materially Expand Manufacturing Capacity of its Lead Asset CNM-Au8®
Aug 10, 2021 07:00AM Clene Reports Second Quarter 2021 Operating and Financial Highlights
Aug 5, 2021 04:01PM Clene Nanomedicine Appoints Dr. Vallerie McLaughlin to its Board of Directors
Aug 5, 2021 07:00AM Clene Reports Positive Top-line Results from its Phase 2 REPAIR Clinical Trials in Parkinson’s Disease and Multiple Sclerosis
Aug 3, 2021 07:00AM Clene to Present at Canaccord Genuity's Annual Growth Conference
View More Recent Stories